The RGX-202 Phase III data is a transformative catalyst that could drive significant upside if the FDA accepts a BLA for accelerated approval. However, the cash runway is tight (into early 2027) and the company will likely need to raise capital before a potential approval. Monitor the Q4 2026 sura-vec wet AMD data readout and the $100M AbbVie milestone payment expected in Q2 2026, which would extend the runway.
Price Chart
Executive Summary
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenue collapsed 93% to $6.4M due to the absence of a prior-year $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration. The cash burn is severe ($150.5M remaining, funding into early 2027). However, the filing is dominated by positive topline Phase III data for RGX-202 in Duchenne: the primary endpoint was met with high statistical significance (93% of patients achieved >10% microdystrophin expression, p<0.0001), and a statistically significant correlation between expression and functional improvement supports a potential accelerated approval pathway in 2027. The clinical hold on RGX-121 was also lifted. The combination of transformative pipeline catalysts and deteriorating financials creates a mixed picture.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $6.4M vs $89.0M YoY, down 93% due to absence of $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration
- Net loss $90.1M ($1.72/share) vs net income $6.1M ($0.12/share) in Q1 2025
- Cash, cash equivalents and marketable securities $150.5M as of March 31, 2026, down from $240.9M at Dec 31, 2025
- Cash runway into early 2027 based on current operational plans
- Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint: 93% of patients achieved >10% microdystrophin expression (p<0.0001)
- Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9)
- Company plans to pursue accelerated approval for RGX-202 with potential commercial launch in 2027
- FDA lifted partial clinical hold on RGX-121 for Hunter syndrome
- AbbVie-partnered sura-vec (ABBV-RGX-314) on track: first patient dosed in DR Phase IIb/III expected Q2 2026; subretinal wet AMD pivotal data expected Q4 2026
- Company will receive $100M milestone from AbbVie upon first patient dosed in NAAVIGATE study
Financial Impact
Revenue declined 93% YoY to $6.4M; net loss widened to $90.1M from net income of $6.1M; cash burn of $90.4M in Q1 2026
Risk Factors
- Cash runway only into early 2027; likely need for dilutive financing before potential RGX-202 approval
- RGX-202 accelerated approval path requires FDA acceptance of surrogate endpoint; regulatory risk remains
- Revenue base collapsed 93% YoY with ZOLGENSMA royalty expiration and no recurring product revenue
- RGX-121 CRL appeal ongoing; path forward uncertain despite clinical hold lift
- Competitive landscape in Duchenne gene therapy (Sarepta, Pfizer, Solid Biosciences)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222768 |
| Document: 0001193125-26-222768-index.html | 0001193125-26-222768 |
| Document: 0001193125-26-222768.txt | 0001193125-26-222768 |
| 8-K Data (Synthetic) | 0001193125-26-222768 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access